A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma

Phase 1

• Conditions: Advanced endometrial carcinoma; MedDRA version: 12.1 Level: LLT Classification code 10014743 Term: Endometrial carcinoma

• Registration Number: EUCTR2008-000634-53-FR
• Lead Sponsor: ARIAD Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-19
• Study Completion: 2012-07-09
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

1. =18 years of age.
2. Patients must have unresectable stage III or IVa, or metastatic (stage IVb), or recurrent histologically-confirmed endometrial cancer.
3. Endometrial cancer will include all carcinomas, including endometrioid carcinoma, papillary serous carcinoma, clear cell carcinoma, and carcinosarcomas. Leiomyosarcomas are not included.
4. Patients must have been treated with at least one line of chemotherapy, but not more than two lines of chemotherapy, and experienced progressive disease. Adjuvant therapy may be allowed, as is up to one line of chemotherapy for recurrent or metastatic disease. These criteria are described in detail in Table 11.1.4.-1.
5. The patient must have at least one measurable lesion that:
• Can be accurately measured in at least one dimension with longest diameter =20 mm using conventional techniques or =10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans).
• Previously irradiated lesions may be considered to be measurable provided: 1) there has been documented progression of the lesion(s) since completion of radiotherapy, and 2) the criteria for measurability as outlined above are met.
6. ECOG performance status = 1.
7. Minimum life expectancy of 3 months.
8. Adequate renal and hepatic function, defined as:
• Total serum bilirubin = institutional ULN unless patient has Gilbert’s syndrome in which case direct bilirubin must be < ULN for the institution.
• AST and/or ALT = 2.5 x ULN for the institution. (or = 5 x ULN if liver metastases are present)
• Alkaline phosphatase < 1.5 x ULN for the institution (if > 1.5 x ULN, then alkaline phosphatase liver fraction must be < 1.5 ULN).
• Serum creatinine = 1.5 x ULN for the institution (or calculated creatinine clearance = 50 mL/min/1.73 m2)
9. Adequate bone marrow function, defined as:
• Total leukocytes = 3.0 x 10^9/L.
• ANC = 1.5 x 10^9/L.
• Platelet count =100 x 10^9/L.
10. Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL.
11. Able to understand and give written informed consent.
12. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment and must use an approved contraceptive method as appropriate from time of study screening until 30 days after the last dose of study drug. Non hormonal methods must be used. Approved contraceptive methods, intra-uterine device, diaphragm with spermicide, cervical cap with spermicide or female condom with spermicide. (Spermicides alone are not an acceptable method of contraception.) .

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Two lines of chemotherapy for recurrent or metastatic disease.
2. Chemotherapy for recurrent or metastatic disease administered within six months of adjuvant therapy.
3. More than two lines of chemotherapy of any type.
4. Prior therapy with hormonal agents for endometrial cancer.
5. Women who are pregnant or lactating.
6. Presence of brain or other central nervous system metastases.
7. Prior therapy with rapamycin, rapamycin analogues or tacrolimus or known sensitivity to these agents
8. Anticancer treatment (chemotherapy, radiotherapy) within 4 weeks prior to randomization. The interval must be = 6 weeks for prior nitrosourea or mitomycin therapy.
9. Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of = grade 1 by NCI Common Terminology Criteria for Adverse Events [CTCAE]), version 3.0.
10. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to randomization. Patients who have recovered from placement of a central venous access port within 2 weeks of Cycle 1 Day 1 will be considered eligible.
11. Another primary malignancy within the past five years (except for non-melanoma skin cancer and cervical carcinoma in situ).
12. Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin).
13. Significant uncontrolled cardiovascular disease including New York Heart Association (NYHA) class III-IV heart failure, unstable angina, or a myocardial infarction within the last six months.
14. Active infection requiring systemic therapy.
15. Known HIV infection.
16. Known hepatitis B or C infection.
17. Newly diagnosed (within 3 months before enrollment) or poorly controlled Type 1 or 2 diabetes.
18. Concurrent treatment with immunosuppressive agents.
19. Patient has a requirement for concurrent treatment with medications that induce or inhibit cytochrome P450 (CYP3A). Patients should be off these medications = 2 weeks prior to the first dose of ridaforolimus.
20. Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient’s safety or interfere with evaluating the safety of the study drug.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified